These are cancer cells that have broken off from a tumor and are traveling through your bloodstream. Finding these cells can sometimes help doctors understand the cancer.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Circulating tumor cells (CTCs) are cancer cells that have broken away from a tumor and entered the bloodstream. From there they can travel to other parts of the body, and a few may settle and grow into new tumors. This spread, called metastasis, is what makes many cancers hard to treat, which is why these cells interest doctors and researchers. CTCs are not a separate disease. They are a sign of a cancer that is already present, and they are usually discussed in the context of a specific cancer such as breast, prostate or colorectal cancer. Most of these cells die in the circulation, so finding them does not mean new tumors will necessarily form. They are also extremely rare compared with the normal cells in blood, which makes them hard to detect.
Circulating tumor cells come from an existing tumor. As a cancer grows, some of its cells gain the ability to loosen their connections, move through surrounding tissue and slip into nearby blood vessels. CTCs are found more often, and in larger numbers, in more advanced cancer, especially once it has already spread. They can also be found in some people with earlier-stage cancer. Their presence reflects how a particular tumor is behaving rather than an outside trigger.
CTCs are not something people are diagnosed with on their own. They are measured with a specialized blood test in someone who already has a cancer diagnosis. The test separates the rare tumor cells from the huge number of ordinary blood cells and counts them. In the United States, one CTC counting system is cleared by the Food and Drug Administration (FDA) for people with metastatic breast, prostate or colorectal cancer. It is meant to be used alongside scans, examinations and other tests, not on its own. In metastatic breast cancer, for example, a count of five or more CTCs in a standard tube of blood (7.5 milliliters, about one and a half teaspoons) is linked with a less favorable outlook than a lower count. The cutoff differs by cancer type (in metastatic colorectal cancer it is three), so the oncology team will say which threshold applies. The test has limits. Some tumor cells lack the surface markers that the test uses to catch them, so a low or zero count does not rule out spread. CTC testing is not an established way to screen for cancer or to diagnose it in someone without a known cancer, and many other CTC tests remain research tools.
There is no treatment aimed at circulating tumor cells themselves. Care focuses on the underlying cancer, using the options that fit its type and stage, such as surgery, radiation, chemotherapy, hormone therapy, targeted therapy or immunotherapy. When treatment works, CTC counts often fall. A CTC count can add information about outlook, but it is not routinely used to choose treatment. Some research suggests it may help in specific situations, such as choosing between chemotherapy and hormone therapy in one type of metastatic breast cancer, but this is not yet standard practice. In a large trial of people with metastatic breast cancer, those whose CTC count stayed high after the first round of chemotherapy did not live longer when they were switched early to a different chemotherapy. The American Society of Clinical Oncology (ASCO) does not recommend routine CTC testing to monitor treatment response in metastatic breast cancer. Researchers continue to study whether analyzing these cells could help match people with specific treatments, mainly within clinical trials.
Many people with cancer will never have a CTC test, because most treatment decisions rest on imaging, tissue biopsies and other blood markers. When a test is done, the result is usually one piece of a larger picture, and its meaning depends on the cancer type, stage and the treatment under way. A higher count is generally associated with a more aggressive course and a shorter time before the cancer grows, while a falling count during treatment tends to go along with a good response. These are patterns seen across groups of people. They cannot predict exactly how one person will do, and a result is best interpreted by the oncology team together with scans and symptoms.
Ask your oncology team to explain a CTC result you have received, particularly whether it changes your treatment plan or how you are monitored. If you are offered a CTC test, it is reasonable to ask what the result would change before having it. Contact your care team promptly about new or worsening symptoms during or after cancer treatment, since those, together with scans, matter more than a CTC count for deciding what happens next.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Circulating Tumor Cells is like, what's helped you, or ask the community a question.